StockNews.com Upgrades Dyne Therapeutics (NASDAQ:DYN) to “Hold”

StockNews.com upgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a sell rating to a hold rating in a report issued on Friday morning.

Several other equities research analysts have also recently commented on DYN. Stifel Nicolaus lifted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a buy rating in a research note on Friday, August 16th. HC Wainwright lifted their target price on Dyne Therapeutics from $48.00 to $55.00 and gave the company a buy rating in a research note on Tuesday, August 13th. Guggenheim lifted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a buy rating in a research note on Thursday, August 15th. Piper Sandler lifted their target price on Dyne Therapeutics from $43.00 to $53.00 and gave the company an overweight rating in a research note on Tuesday, August 13th. Finally, Jefferies Financial Group raised their price target on Dyne Therapeutics from $36.00 to $42.00 and gave the stock a buy rating in a research report on Monday, May 20th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of Buy and an average price target of $50.60.

Dyne Therapeutics Price Performance

DYN stock opened at $46.09 on Friday. The business has a fifty day moving average price of $41.49 and a 200 day moving average price of $32.60. Dyne Therapeutics has a fifty-two week low of $6.40 and a fifty-two week high of $47.45. The stock has a market capitalization of $4.03 billion, a price-to-earnings ratio of -11.61 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, equities analysts expect that Dyne Therapeutics will post -2.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Dyne Therapeutics news, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the transaction, the chief operating officer now directly owns 148,792 shares in the company, valued at $5,256,821.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,136 shares of Dyne Therapeutics stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $31.34, for a total transaction of $66,942.24. Following the transaction, the insider now directly owns 147,511 shares in the company, valued at $4,622,994.74. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the transaction, the chief operating officer now owns 148,792 shares in the company, valued at $5,256,821.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 163,676 shares of company stock worth $5,270,510. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its holdings in shares of Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after purchasing an additional 352 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after purchasing an additional 796 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Dyne Therapeutics by 5.9% in the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after purchasing an additional 857 shares in the last quarter. Finally, Wetzel Investment Advisors Inc. bought a new stake in shares of Dyne Therapeutics in the first quarter valued at about $28,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.